8-K: Ocugen Receives FDA Approval for Expanded Access Program of OCU400 for Retinitis Pigmentosa

Ocugen has received FDA approval to begin an expanded access program for OCU400, a gene therapy for adults with retinitis pigmentosa, while a Phase 3 trial is underway.

Summary

• Ocugen has announced that the FDA has approved its expanded access program (EAP) for OCU400, a gene therapy for retinitis pigmentosa (RP).
• The EAP will allow adult patients with RP, aged 18 and older, to access OCU400 outside of the ongoing Phase 3 clinical trial.
• This program is intended for patients with early, intermediate, or advanced RP who have at least minimal retinal preservation.
• The EAP also includes patients who participated in the Phase 1/2 study and those who did not meet the inclusion criteria for the Phase 1/2 or Phase 3 trials but could benefit from OCU400.
• Ocugen is currently enrolling patients in the Phase 3 liMeliGhT clinical trial, which has a sample size of 150 participants.
• The company anticipates BLA and MAA approval for OCU400 in 2026.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the FDA approval of the expanded access program and the progress of the Phase 3 trial. The company is moving forward with its plans and has a clear path to potential regulatory approval.

Positives

• The FDA approval of the EAP provides access to OCU400 for RP patients who may not have other treatment options.
• OCU400 has received orphan drug and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA.
• The European Medicines Agency (EMA) has accepted the U.S.-based trial for submission of a Marketing Authorization Application (MAA).
• The EAP strengthens Ocugen's commitment to serving RP patients, estimated to be 300,000 in the U.S. and Europe and 1.6 million globally.
• OCU400 has the potential to address multiple retinal diseases caused by mutations in multiple genes with one product.

Risks

• The success of the clinical trials and the regulatory approval process are subject to risks and uncertainties.
• Preliminary clinical trial results may not be indicative of final clinical data.
• Unfavorable new clinical trial data may emerge in ongoing clinical trials.
• Clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities.

Future Outlook

Ocugen anticipates BLA and MAA approval for OCU400 in 2026 and plans to continue its clinical trials and expand access to the therapy.

Management Comments

• Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen, stated that each clinical milestone achieved by OCU400 brings them closer to providing a potential one-time treatment for life to patients living with RP.
• Dr. Huma Qamar, Ocugen's Chief Medical Officer, said they are pleased to make OCU400 available to patients beyond their Phase 3 liMeliGhT clinical trial through the EAP.
• Lejla Vajzovic, MD, FASRS, Director, Duke Surgical Vitreoretinal Fellowship Program, expressed encouragement by the therapeutic potential of OCU400 to provide long-term benefit.

Industry Context

This announcement is significant in the gene therapy space, particularly for rare retinal diseases like retinitis pigmentosa, where treatment options are limited. The expanded access program allows patients to access a promising therapy while the company continues its clinical trials.

Comparison to Industry Standards

• The use of modifier gene therapy, targeting multiple genes rather than single-gene replacement, is a novel approach in the treatment of retinal diseases.
• Companies like Spark Therapeutics (now part of Roche) have pioneered gene therapy for retinal diseases, but their focus has been on single-gene replacement.
• Ocugen's approach with OCU400, targeting a master gene regulator, could potentially address a broader range of mutations and diseases compared to single-gene therapies.
• The expanded access program is similar to programs offered by other companies to provide early access to promising therapies before full regulatory approval.

Stakeholder Impact

• Shareholders will likely view the FDA approval and progress of the clinical trial positively.
• Patients with retinitis pigmentosa will have access to a potential new treatment option through the EAP.
• Clinicians will have the opportunity to participate in the EAP and gain experience with OCU400.
• Employees of Ocugen will be involved in the execution of the EAP and clinical trials.

Next Steps

• Ocugen will work with clinicians, patients, and the RP community to provide access to OCU400 through the EAP.
• The company will continue to enroll patients in the Phase 3 liMeliGhT clinical trial.
• Ocugen will pursue BLA and MAA approval for OCU400.

Key Dates

Keywords

retinitis pigmentosa, OCU400, gene therapy, expanded access program, FDA, clinical trial, modifier gene therapy, orphan drug, RMAT, EMA, BLA, MAA